Antibody Information

General Information of This Antibody

Antibody ID	ANI0JFJCU
Antibody Name	mu-alpha-EGFR
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1-kappa
Antigen Name	Epidermal growth factor receptor (EGFR)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

Mu-Alpha-EGFR-172 [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.30 nM	High EGFR expression (EGFR+++)
Method Description	Serial dilutions of IMSA172 or its conjugates with the indicated antibodies (ADCs) were incubated with THP1-ISG-Luc or this cell line stably expressing human EGFR (THP1-ISG-luc-EGFR; B and D) for 16 h, and the interferon response was measured by luciferase assay.
In Vitro Model	Acute monocytic leukemia	THP1-Lucia ISG cells		CVCL_X587
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 10.00 uM	Negative EGFR expression (EGFR-)
Method Description	Serial dilutions of IMSA172 or its conjugates with the indicated antibodies (ADCs) were incubated with THP1-ISG-Luc or this cell line stably expressing human EGFR (THP1-ISG-luc-EGFR; B and D) for 16 h, and the interferon response was measured by luciferase assay.
In Vitro Model	Acute monocytic leukemia	THP1-Lucia ISG cells		CVCL_X587

References

Ref 1	Tumor-targeted delivery of a STING agonist improvescancer immunotherapy. Proc Natl Acad Sci U S A. 2022 Dec 6;119(49):e2214278119.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.